Christian B. Voigtlander Sells 1,962 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

ICU Medical Price Performance

NASDAQ ICUI opened at $157.75 on Wednesday. ICU Medical, Inc. has a 1-year low of $83.26 and a 1-year high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a 50-day moving average of $175.98 and a two-hundred day moving average of $146.15.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds have recently added to or reduced their stakes in ICUI. Innealta Capital LLC acquired a new position in shares of ICU Medical in the second quarter worth $32,000. Hexagon Capital Partners LLC boosted its holdings in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP grew its stake in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares in the last quarter. EntryPoint Capital LLC increased its holdings in ICU Medical by 731.5% during the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares during the period. Finally, Russell Investments Group Ltd. raised its position in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 173 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ICUI has been the topic of several recent analyst reports. Jefferies Financial Group began coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. KeyCorp boosted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Raymond James boosted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.